• Discover Astex
    • Our Mission & Values
    • Our Leadership Team
    • Our History
    • Corporate Social Responsibility
  • R&D
    • Clinical Pipeline
      • Partnered Products and Programs
        • Kisqali® (ribociclib) CDK4/6 inhibitor (Oncology)
        • Balversa® (erdafitinib) FGFr inhibitor (Oncology)
        • Truqap® PKB/Akt Inhibitor (Oncology)
        • KRAS Oncogene (Oncology)
        • Beroterkib (ASTX029) Extracellular Signal-Related Protein Kinases (ERK 1/2) Inhibitor (Solid Tumors)
        • ASTX295 Oral Murine Double Minute 2 (MDM2) antagonist (Solid Tumors)
        • SHP2 (Oncology)
        • P53 tumour suppressor protein (Oncology)
      • Proprietary Products and Programs
        • Tolinapant (ASTX660) Dual IAP Antagonist (T-cell Lymphomas)
    • Pyramid™ Discovery Platform
    • Oncology and CNS Discovery
    • Sustaining Innovation Postdocs
  • Partnering
  • Our People & Culture
    • Career Opportunities
  • Media
    • Press Releases
    • Conferences & Meetings
    • Presentations & Publications
    • Interactive Scientific Resources
      • Interactive Software
    • Astex in the News
  • Contact
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu
You are here: Home1 / 20072 / SuperGen Reports Initiation of Multi-arm Phase 1b Trial of Novel Tyrosine...

SuperGen Reports Initiation of Multi-arm Phase 1b Trial of Novel Tyrosine Kinase Inhibitor

17 December 2007/in 2007, News

SuperGen Reports Initiation of Multi-arm Phase 1b Trial of Novel Tyrosine Kinase Inhibitor

https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg 0 0 webadmin https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg webadmin2007-12-17 13:07:252016-11-28 13:35:12SuperGen Reports Initiation of Multi-arm Phase 1b Trial of Novel Tyrosine Kinase Inhibitor

© Astex Pharmaceuticals
All rights reserved

astex

Useful links

  • Home
  • Sitemap
  • Privacy Policy
  • Terms of Use
  • Legal
  • LinkedIn

Member of the Otsuka Group

A selection of photos on this website
is courtesy of Valerio Berdini

Link to: SuperGen’s Novel Hypomethylating Agent Highlighted at American Society of Hematology Annual Meeting Link to: SuperGen’s Novel Hypomethylating Agent Highlighted at American Society of Hematology Annual Meeting SuperGen’s Novel Hypomethylating Agent Highlighted at American Society... Link to: Astex Receives IND Approval for its Small Molecule HSP90 Inhibitor AT13387; Astex Announces Extension of Drug Discovery Alliance Link to: Astex Receives IND Approval for its Small Molecule HSP90 Inhibitor AT13387; Astex Announces Extension of Drug Discovery Alliance Astex Receives IND Approval for its Small Molecule HSP90 Inhibitor AT13387;...
Scroll to top Scroll to top Scroll to top
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok